Chong Kun Dang Pharmaceutical종근당
185750 · KOSPI · ₩185750 · 종근당
Broker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 8 | Heungkuk Securities | [Pharma/Bio/Cosmetics] Chong Kun Dang: Stable core business growth amid new drug trials progressing | — | — | — | −4.2% | Read ↗ |
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Chong Kun Dang's profits have fallen sharply from 2023 peaks, and the shares trade near their 52-week low.
Trailing revenue is about ₩1.78T with a thin 4.3% operating margin, and free cash flow is negative at about -₩65B. The share price is ₩64,700, down 19.4% over one year and close to its 52-week low of ₩63,000, with a P/E of 11.2 and P/B of 0.9.
What stands out
- Revenue has grown from about ₩1.49T in 2022 to about ₩1.69T in 2025, but operating income fell from ₩247B in 2023 to ₩81B in 2025.
- Trailing debt of about ₩428B exceeds cash of about ₩192B, and liabilities are 83.3% of equity.
- The DCF-based fair value range in the data is ₩34,216 to ₩192,813, with a base case of ₩90,197; the base case sits above the current price, but the range is very wide.
- Foreign ownership is 16% and roughly flat over 60 days, while retail investors were net sellers of about ₩4.4B over the last 20 days.
- Recent news is mainly about product launches and a premium nursing home opening, and the filings include several amended half-year reports for June 2026 and shareholding reports.
What to watch
- The amended June 2026 half-year reports, to see whether any figures change.
- Free cash flow and borrowing levels, given negative trailing free cash flow and ₩428B of borrowings.
- Shareholder activity, including changes in the largest shareholder's holdings and 5%+ holding reports filed in October.
Data as of Oct 23, 2026 · written Oct 26, 2026
This is not financial advice.
Also known as: Chong Kun Dang Pharmaceutical / 종근당 / 185750 / KRX:185750
Source: KRX statistical information